@article{CCO6014,
author = {Grace S. Li},
title = {Professor Jon Wigginton: where we are standing in immunotherapy},
journal = {Chinese Clinical Oncology},
volume = {4},
number = {1},
year = {2015},
keywords = {},
abstract = {Prof. Jon Wigginton (Figure 1) was previously the Therapeutic Area Head, Immuno-Oncology, Early Clinical Research and Executive Director, Discovery Medicine- Clinical Oncology at Bristol-Myers Squibb (BMS), where he led the early clinical development of the BMS Immuno- Oncology portfolio including anti-PD-1 and anti-PD-L1. Prior to joining BMS, Dr. Wigginton was the Director of Clinical Oncology at Merck Research Laboratories, where he led early- and late-stage clinical development teams for small molecules and biologics. During his academic career, he held several positions at the National Cancer Institute Center for Cancer Research (NCI-CCR), including Head of Investigational Biologics Section, Pediatric Oncology Branch. Dr. Wigginton is also past president of the International Society for the Biological Therapy of Cancer (now SITC). He is the author of over 50 manuscripts and reviews and is the recipient of multiple awards for scientific accomplishment from sources including the NIH, NCI, USPHS, iSBTc, ISICR, Children’s Cancer Foundation, Merck and BMS. Dr. Wigginton received his M.D. and B.S. in Biology, with distinction, from the University of Michigan.},
issn = {2304-3873}, url = {https://cco.amegroups.org/article/view/6014}
}